Canoe Financial LP Lowers Holdings in Becton, Dickinson and Company (NYSE:BDX)

Canoe Financial LP cut its holdings in Becton, Dickinson and Company (NYSE:BDX) by 6.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,841 shares of the medical instruments supplier’s stock after selling 2,937 shares during the quarter. Canoe Financial LP’s holdings in Becton, Dickinson and Company were worth $9,039,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Sound Income Strategies LLC boosted its holdings in Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 44 shares during the last quarter. Central Pacific Bank Trust Division boosted its stake in shares of Becton, Dickinson and Company by 22.5% during the 3rd quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock worth $59,000 after acquiring an additional 45 shares during the last quarter. Tompkins Financial Corp grew its position in shares of Becton, Dickinson and Company by 44.2% during the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 46 shares during the period. Birch Capital Management LLC increased its stake in shares of Becton, Dickinson and Company by 0.4% in the 3rd quarter. Birch Capital Management LLC now owns 11,773 shares of the medical instruments supplier’s stock worth $2,838,000 after purchasing an additional 48 shares in the last quarter. Finally, Radnor Capital Management LLC lifted its position in Becton, Dickinson and Company by 1.7% during the third quarter. Radnor Capital Management LLC now owns 2,937 shares of the medical instruments supplier’s stock valued at $708,000 after purchasing an additional 48 shares in the last quarter. 86.97% of the stock is owned by institutional investors.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 2,838 shares of the stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $223.33, for a total transaction of $633,810.54. Following the completion of the transaction, the executive vice president now owns 6,141 shares in the company, valued at $1,371,469.53. This trade represents a 31.61 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Roland Goette sold 4,483 shares of the firm’s stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $221.01, for a total value of $990,787.83. Following the completion of the sale, the executive vice president now directly owns 24,345 shares of the company’s stock, valued at $5,380,488.45. The trade was a 15.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 8,747 shares of company stock valued at $1,949,520. 0.36% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

BDX has been the subject of a number of analyst reports. Evercore ISI upped their price target on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. StockNews.com cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Finally, Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price target for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $283.50.

Becton, Dickinson and Company Stock Up 0.5 %

Shares of BDX opened at $237.57 on Friday. The business’s 50 day moving average is $226.95 and its 200 day moving average is $232.53. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $248.42. The company has a market capitalization of $68.90 billion, a PE ratio of 40.00, a price-to-earnings-growth ratio of 1.69 and a beta of 0.39.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.77 by $0.04. The firm had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The company’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same quarter last year, the business posted $3.42 earnings per share. Research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th were given a dividend of $1.04 per share. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. The ex-dividend date of this dividend was Monday, December 9th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.75%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 70.03%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.